<DOC>
	<DOCNO>NCT02528019</DOCNO>
	<brief_summary>Inhibition dipeptidyl peptidase-4 ( DPP-4 ) sodium-glucose co-transporter type 2 ( SGLT2 ) propose therapeutic target type 2 diabetes . However , DPP-4 inhibitor SGLT2 inhibitor exert protective action diabetic complication addition glucose-lowering effect remain unknown .</brief_summary>
	<brief_title>Metabolic Cardiovascular Effects Dipeptidyl Peptidase-4 ( DPP-4 ) Sodium-glucose Co-transporter Type 2 ( SGLT2 ) Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Complications</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Clinical diagnosis type 2 diabetic patient Must able swallow tablet never receive DPP4 inhibitor SGLT2 inhibitor uncontrolled diabetes ( fast plasma glucose &gt; 200 mg/dL ) receive insulin therapy hepatic disorder ( 2.5 fold great increase aspartate transaminase alanine transaminase level upper limit normal ) inflammatory disorder neoplastic disorder recent ( &lt; 3months ) acute coronary syndrome stroke acute infection</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>